These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 30642555)
1. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555 [TBL] [Abstract][Full Text] [Related]
3. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers and prognostic factors for malignant pleural mesothelioma. Vigneri P; Martorana F; Manzella L; Stella S Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920 [TBL] [Abstract][Full Text] [Related]
6. Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018). Wu L; Dell'Anno I; Lapidot M; Sekido Y; Chan ML; Kohno M; Serre-Beinier V; Felley-Bosco E; de Perrot M Lung Cancer; 2019 Jan; 127():138-145. PubMed ID: 30642542 [TBL] [Abstract][Full Text] [Related]
14. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343 [TBL] [Abstract][Full Text] [Related]
15. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Husain AN; Colby TV; Ordóñez NG; Allen TC; Attanoos RL; Beasley MB; Butnor KJ; Chirieac LR; Churg AM; Dacic S; Galateau-Sallé F; Gibbs A; Gown AM; Krausz T; Litzky LA; Marchevsky A; Nicholson AG; Roggli VL; Sharma AK; Travis WD; Walts AE; Wick MR Arch Pathol Lab Med; 2018 Jan; 142(1):89-108. PubMed ID: 28686500 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study. Hakim SA; Abou Gabal HH Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556 [No Abstract] [Full Text] [Related]
17. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach. Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167 [TBL] [Abstract][Full Text] [Related]
18. Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group. Armato SG; Katz SI; Frauenfelder T; Jayasekera G; Catino A; Blyth KG; Theodoro T; Rousset P; Nackaerts K; Opitz I Lung Cancer; 2024 Jul; 193():107832. PubMed ID: 38875938 [TBL] [Abstract][Full Text] [Related]
19. Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Armato SG; Francis RJ; Katz SI; Ak G; Opitz I; Gudmundsson E; Blyth KG; Gupta A Lung Cancer; 2019 Apr; 130():108-114. PubMed ID: 30885330 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma. Liu H; Wu L; Ji K; Wang W Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]